A RETROSPECTIVE case series has identified ophthalmic complications in patients using the antidiabetic drugs semaglutide and ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...

Recent studies have shed light on these medications’ benefits and potential risks. Ozempic’s common side effects include nausea, diarrhea, constipation, and acid reflux, which are generally mild ...

Obesity significantly impacts cardiovascular health, increasing risks such as left ventricular hypertrophy, atherosclerosis, ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular ...